Skip to main content

Table 9 Autoantibodies and fibromyalgia (FM)

From: Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome

Reference

Year of study

Number of FM patients

Number of control individuals

Objective measure

Findings

Klein and colleagues [82]

1992

50

?HC

Antiserotonin

Increased in FMS

    

Antiganglioside

Increased in FMS

    

Antiphospholipid

Increased in FMS

Klein and Berg [81]

1995

100

42 CFS, ?HC

Antiserotonin

Increased in CFS and FMS

    

Antigangliosides

Increased in CFS and FMS

    

Antiphospholipid

Increased in CFS and FMS

Werle and colleagues [83]

2001

203

64

Antiserotonin

Increased

    

Antithromboplastin

Increased

    

Antiganglioside

No difference

    

Gm1

No difference

Wilson and colleagues [84]

1999

47

16 OA,12 RA, banked sera, 15 myositis, 30 RA, 30 SLE, 30 SSc

Antipolymer antibody

Increased in antipolymer antibodies, higher in severe versus mild

Nishikai and colleagues [85]

2001

125

114 CFS, ?psych, ?CTD

Anti-68/48 kDa

Increased in FMS and CFS

    

Anti-45 kDa

Increased in FMS and CFS

  1. CFS, chronic fatigue syndrome; CTD, connective tissue disease; FMS, fibromyalgia syndrome; HC, healthy control individuals; OA, osteoarthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythmatosus; SSc, systemic sclerosis.